Notably, pathways such as glycerophospholipid metabolism have been identified to modulate insulin resistance and lipid metabolism, thereby mitigating cardiac damage in models of diabetic cardiomyopathy (Dong et al., 2021; Jiang et al., 2022). This evidence concerns the gene INS and diabetic cardiomyopathy.